Quick Answer
AVANOS MEDICAL, INC. reported Total Revenue of $701.20 million for fiscal year 2025.
AVANOS MEDICAL, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $701.20M +1.9% |
$687.80M +2.2% |
$673.30M -1.6% |
$684.10M +16.5% |
$587.00M -17.9% |
$714.80M +2.5% |
| Revenue (ASC 606) | $701.20M +1.9% |
$687.80M +2.2% |
$673.30M -1.6% |
$684.10M +16.5% |
$587.00M -17.9% |
$714.80M +2.5% |
| Net Income | -$72.90M +81.4% |
-$392.10M -534.5% |
-$61.80M -222.4% |
$50.50M +701.6% |
$6.30M +121.7% |
-$29.00M +36.8% |
| Diluted EPS | -$1.57 +81.6% |
-$8.53 -546.2% |
-$1.32 -223.4% |
$1.07 +723.1% |
$0.13 +121.3% |
-$0.61 +36.5% |
| Total Assets | $1.07B -7.0% |
$1.15B -31.8% |
$1.69B -5.3% |
$1.79B +11.4% |
$1.60B -4.1% |
$1.67B -7.0% |
| Cash and Equivalents | $89.80M -16.6% |
$107.70M +22.8% |
$87.70M -31.3% |
$127.70M +7.8% |
$118.50M +6.3% |
$111.50M -45.7% |
| Long-Term Debt | $90.30M -27.9% |
$125.30M -21.4% |
$159.40M -29.6% |
$226.30M +74.1% |
$130.00M -27.8% |
$180.00M -27.4% |
| Stockholders Equity | $778.20M -6.1% |
$828.50M -33.0% |
$1.24B -4.3% |
$1.29B +1.6% |
$1.27B +0.7% |
$1.26B -0.8% |
| R&D Expense | $23.30M -11.1% |
$26.20M -3.7% |
$27.20M -6.8% |
$29.20M -4.6% |
$30.60M -12.3% |
$34.90M -7.4% |
| Operating Income | -$61.60M +84.5% |
-$396.20M -9533.3% |
$4.20M -88.2% |
$35.50M +191.0% |
-$39.00M +19.6% |
-$48.50M +12.9% |
| Gross Profit | $353.90M -7.2% |
$381.30M +0.4% |
$379.70M -3.7% |
$394.20M +31.8% |
$299.20M -19.3% |
$370.90M -7.8% |
| Shares Outstanding | 46.46M +1.1% |
45.96M -0.5% |
46.17M -0.8% |
46.53M -3.5% |
48.21M +0.6% |
47.92M +0.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $177.80M | +4.3% | +1.6% |
| Revenue (ASC 606) | September 30, 2025 | $177.80M | +4.3% | +1.6% |
| Net Income | September 30, 2025 | -$1.40M | -132.6% | +98.2% |
| Diluted EPS | September 30, 2025 | -$0.03 | -133.3% | +98.2% |
| Total Assets | September 30, 2025 | $1.07B | -35.5% | +2.8% |
| Cash and Equivalents | September 30, 2025 | $70.50M | -20.8% | -21.9% |
| Long-Term Debt | September 30, 2025 | $93.40M | -38.8% | -2.4% |
| Stockholders Equity | September 30, 2025 | $778.00M | -36.7% | +0.2% |
| R&D Expense | September 30, 2025 | $6.00M | -16.7% | +3.4% |
| Operating Income | September 30, 2025 | $100.0K | -99.2% | +100.1% |
| Gross Profit | September 30, 2025 | $86.00M | -7.4% | -6.6% |
| Shares Outstanding | September 30, 2025 | 46.42M | +1.0% | +0.2% |
- AVANOS MEDICAL, INC. reported Total Revenue of $701.20 million for fiscal year 2025.
- AVANOS MEDICAL, INC. showed an increase of +1.9% in Total Revenue compared to the prior fiscal year.
- AVANOS MEDICAL, INC. reported Revenue (ASC 606) of $701.20 million for fiscal year 2025.
- AVANOS MEDICAL, INC. showed an increase of +1.9% in Revenue (ASC 606) compared to the prior fiscal year.
- AVANOS MEDICAL, INC. reported Net Income of -$72.90 million for fiscal year 2025.
- AVANOS MEDICAL, INC. showed an increase of +81.4% in Net Income compared to the prior fiscal year.
- AVANOS MEDICAL, INC. reported Diluted EPS of $1.57 per share (loss) for fiscal year 2025.
- AVANOS MEDICAL, INC. showed an increase of +81.6% in Diluted EPS compared to the prior fiscal year.
- AVANOS MEDICAL, INC. reported Total Assets of $1.07 billion for fiscal year 2025.
- AVANOS MEDICAL, INC. showed a decrease of -7.0% in Total Assets compared to the prior fiscal year.
- AVANOS MEDICAL, INC. reported Cash and Equivalents of $89.80 million for fiscal year 2025.
- AVANOS MEDICAL, INC. showed a decrease of -16.6% in Cash and Equivalents compared to the prior fiscal year.
- AVANOS MEDICAL, INC. reported Long-Term Debt of $90.30 million for fiscal year 2025.
- AVANOS MEDICAL, INC. showed a decrease of -27.9% in Long-Term Debt compared to the prior fiscal year.
- AVANOS MEDICAL, INC. reported Stockholders Equity of $778.20 million for fiscal year 2025.
- AVANOS MEDICAL, INC. showed a decrease of -6.1% in Stockholders Equity compared to the prior fiscal year.
- AVANOS MEDICAL, INC. reported R&D Expense of $23.30 million for fiscal year 2025.
- AVANOS MEDICAL, INC. showed a decrease of -11.1% in R&D Expense compared to the prior fiscal year.
- AVANOS MEDICAL, INC. reported Operating Income of -$61.60 million for fiscal year 2025.
- AVANOS MEDICAL, INC. showed an increase of +84.5% in Operating Income compared to the prior fiscal year.
- AVANOS MEDICAL, INC. reported Gross Profit of $353.90 million for fiscal year 2025.
- AVANOS MEDICAL, INC. showed a decrease of -7.2% in Gross Profit compared to the prior fiscal year.
- AVANOS MEDICAL, INC. reported Shares Outstanding of 46.46 million shares for fiscal year 2025.
- AVANOS MEDICAL, INC. showed an increase of +1.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: